Diffuse Large B-Cell Lymphoma (ASH KOL Insights) Basic Listing

Insights on Diffuse Large B-Cell Lymphoma

From the ASH Annual Meeting & Exposition

Conference Coverage

Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers

02/11/2026

Olalekan O. Oluwole

Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...

Olalekan Oluwole, MD, MBBS...

02/11/2026

Oncology

Conference Coverage

Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis

01/26/2026

Olalekan O. Oluwole

Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.

Olalekan Oluwole, MD, MBBS,...

01/26/2026

Oncology

Conference Coverage

Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma

01/22/2026

Jeff P. Sharman

Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.

Jeff Sharman, MD, reported phase...

01/22/2026

Oncology

Conference Coverage

Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2

12/23/2025

Chan Cheah, MBBS

Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.

Epcoritamab plus R-mini-CHOP...

12/23/2025

Oncology

Conference Coverage

Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy

12/09/2025

Bilal Abid, MD, MS, FACP, MRCP, FRCP

According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.

According to results presented...

12/09/2025

Oncology

Conference Coverage

Healthcare Resource Utilization for Patients With DLBCL and MM Comparable Between New and Established CAR T-Cell Therapy Centers

12/09/2025

Olalekan O. Oluwole

Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.

Newly authorized US CAR T-cell...

12/09/2025

Oncology

Conference Coverage

Emergence of Novel Composite End Points Toxicity/PFS and Toxicity-Free CR to Benchmark Safety and Efficacy of CAR-T Cell Therapy for DLBCL

12/08/2025

Veronika Bachanova, MD, PhD

At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...

At the ASH 2025 Annual Meeting,...

12/08/2025

Oncology

Conference Coverage

OLYMPIA-3 Trial: Odronextamab With CHOP Demonstrates Strong Efficacy and Manageable Safety for Patients With Newly Diagnosed DLBCL

12/07/2025

Jean-Marie Michot, MD

Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.

Odronextamab combined with CHOP...

12/07/2025

Oncology

Videos

Long-Term Follow-up of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients With Intermediate- or High-Risk DLBCL

01/07/2025

Gilles Salles, MD, PhD

According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant PFS benefit vs R-CHOP among patients with intermediate-...

According to a prolonged...

01/07/2025

Oncology

Videos

Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma

01/06/2025

Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...

Subcutaenous mosunetuzumab plus...

01/06/2025

Oncology

Recent News

News

Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

05/22/2026

Emily Estrada

Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.

Interim results from cohort 1 of...

05/22/2026

Oncology

News

Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer

05/22/2026

Emily Estrada

Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...

Long-term results from a phase 3...

05/22/2026

Oncology

FDA Approval

FDA Approves Datopotamab Deruxtecan for Patients With Triple-Negative Breast Cancer

05/22/2026

Emily Estrada

Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.

Based on results from the...

05/22/2026

Oncology

News

Ipatasertib Plus Fulvestrant and Palbociclib Shows Strong Preliminary Activity in HR-Positive, HER2-Negative Breast Cancer

05/21/2026

Stephanie Holland

Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...

Clinical...

05/21/2026

Oncology

News

Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas

05/21/2026

Stephanie Holland

Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.

Long-term follow-up results from...

05/21/2026

Oncology

News

Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer

05/20/2026

Stephanie Holland

Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.

Results from a phase 2 trial...

05/20/2026

Oncology

News

Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer

05/20/2026

Stephanie Holland

Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.

Results from a phase 3 trial...

05/20/2026

Oncology

News

Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer

05/19/2026

Emily Estrada

Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.

Results from the phase 3...

05/19/2026

Oncology

News

Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer

05/19/2026

Emily Estrada

Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.

Results from a prospective study...

05/19/2026

Oncology

News

Durvalumab Plus BCG Delays High-Risk Recurrence in Non-Muscle-Invasive Bladder Cancer

05/19/2026

Stephanie Holland

Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.

Updated results from the POTOMAC...

05/19/2026

Oncology